<DOC>
	<DOCNO>NCT00485121</DOCNO>
	<brief_summary>The purpose study investigate effect add ezetimibe statin therapy level inflammatory marker adipokines patient atherosclerosis disease feature metabolic syndrome , whose LDL-c remain target ( &gt; 2.0 mmol/L ) despite statin monotherapy . We hypothesize addition Ezetimibe ( 10mg per day 12 week ) ongoing statin therapy patient atherosclerosis feature metabolic syndrome favourably modify level inflammatory biomarkers adipokines .</brief_summary>
	<brief_title>Effects Ezetimibe Add-On Statin Therapy Adipokine Production Obese Metabolic Syndrome Patients With Atherosclerosis</brief_title>
	<detailed_description>Atherosclerotic cardiovascular disease remain leading cause death industrialize nation despite major advance diagnosis , treatment prevention . While trend last half century show general decline age-adjusted death rate heart disease stroke , increase epidemic obesity , follow closely insulin resistance type 2 diabetes likely slow decline promise reverse trend . Obesity mediate increase cardiovascular disease risk multiple pathway . Adipose tissue longer view passive repository triacylglycerol storage source free fatty acid ( FFAs ) . It recognize rich source proinflammatory mediator , many cytokine , growth factor hormones directly contribute proinflammatory milieu mediate vascular injury , insulin resistance ultimately impact cardiovascular health . These proinflammatory adipocytokines , adipokines include tumor necrosis factor- α ( TNF α ) , interleukin-6 ( IL-6 ) , leptin , plasminogen activator inhibitor-1 ( PAI-1 ) , angiotensinogen , resistin recently C-reactive protein ( CRP ) . On hand , nitric oxide ( NO ) another adipokine call adiponectin confer protection inflammation obesity-linked insulin resistance . The evolve role augment adipokine production obese insulin resistant state cardiovascular disease risk open new avenue therapeutic intervention . Treatment metabolic syndrome need embrace new strategy reduce burden proinflammatory adipokines . Lifestyle intervention remain cornerstone therapy , consideration also give number drug decrease inflammatory adipokines . Ezetimibe selectively inhibit absorption biliary dietary cholesterol phytosterols intestinal brush border . When add coadministered statin , ezetimibe produce significant incremental LDL-C , apolipoprotein ( apo ) B , triglyceride ( TG ) reduction , beneficial effect high-density lipoprotein cholesterol ( HDL-C ) compare statin monotherapy , well tolerate low incidence side effect . It previously demonstrate 12 week trial addition ezetimibe simvastatin result significant incremental reduction CRP compare simvastatin monotherapy . The outlined study protocol investigate effect add ezetimibe statin therapy level inflammatory marker adipokines patient atherosclerosis feature metabolic syndrome , whose LDL-c remain target ( &gt; 2.0 mmol/L ) despite statin monotherapy .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Patients statin therapy ( dose change within past 4 week ) LDLc &gt; 2mmol/l Presence atherosclerosis ( CHD* and/or cerebrovascular disease** and/ peripheral arterial disease ( PAD ) *** ) plus least one following : 1 . Metabolic Syndrome ( accord modify NCEP ATP III criterion , use waist circumference cutoff 80 cm woman 90 cm men subject Asian origin cutoff 88 cm woman 102 cm men Caucasian subject ) 2 . Obesity ( BMI &gt; 30 Kg/m2 waist circumference &gt; 102 men &gt; 88 woman . For subject Asian origin cutoff value 25 , 90 80 respectively ) * CHD define ( one follow ) : previous myocardial infarction ; coronary angiography demonstrate least 50 % diameter stenosis epicardial coronary artery major branch ; previous percutaneous transluminal coronary angioplasty ( PTCA ) without stent implantation ( atherectomy include ) previous coronary artery bypass grafting ( CABG ) ** Cerebrovascular disease define ( one follow ) : prior ischemic stroke , document TIA , flowlimiting stenosis extracranial artery document Doppler angiography . *** PAD define ( one follow ) : prior peripheral arterial revascularization ( PTA surgery ) , amputation , document intermittent claudication ABI &lt; 0.9 Women pregnant , breast feeding , use reliable method contraception Clinical sign congestive heart failure measure leave ventricular ejection fraction &lt; 40 % Hemodynamically significant valvular heart disease hypertrophic obstructive cardiomyopathy Renal dysfunction ( creatinine &gt; 1.8 x ULN ) Hepatic disease ( liver function test &gt; 1.5 x ULN [ upper limit normal ] ) Other significant laboratory abnormality investigator feel may compromise patient 's safety participation study History systemic inflammatory disease ( rheumatoid arthritis , inflammatory bowel disease , systemic lupus erythematous ) , myositis/myopathic process , cancer ) HIV Use steroid chemotherapy drug within past year chronic use nonsteroidal antiinflammatory drug besides aspirin ( use &gt; 2 week within past year ) ; Known hypersensitivity Ezetimibe Participation another clinical study concurrently within 30day phase prior screen entry present study Unwilling provide write informed consent study participant and/or Unreliability study participant base investigator 's prior knowledge patient , inability willingness participate complete study presence concurrent physical psychological disorder may make impractical patient participate complete study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Ezetimibe</keyword>
	<keyword>Statin</keyword>
	<keyword>Low- density lipoprotein cholesterol</keyword>
	<keyword>Adipokine</keyword>
	<keyword>Adiponectin</keyword>
	<keyword>C-reactive protein</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Obesity</keyword>
</DOC>